News

CB-5083 is a first-in-class, oral inhibitor of p97, a major enzyme that controls various aspects of protein homeostasis. Currently, the company is evaluating CB-5083 in two Phase I

The results demonstrated that, following an initial 10 week combination therapy treatment period, patients who continued to receive a combination of topical OHR-102 BID plus Lucentis achieved greater

The InnFocus MicroShunt is in studies to prove it is a safe, effective, sustainable, and easy-to-perform alternative for the surgical treatment for early stage to late stage glaucoma

The acquisition includes 19 solid-oral dosage products, and 3 oral suspension products. ANI will initially focus to tech transfer four products that qualify as CBE30 filings into ANI’s

Dr. Glenn J. Jaffe, Robert Machemer Professor of Ophthalmology at Duke University School of Medicine in Durham, NC, presented the top line results during an oral abstract session

Consideration for the acquisition will be in the form of 420,000 of Aequus common shares to be issued upon closing, and an additional 2,940,000 common shares which will

BLU-554 is indicated to treat advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, while BLU-285 is for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST). The company noted that it is also

The trial showed that atezolizumab shrank tumors in people with locally advanced or metastatic urothelial bladder cancer (UBC) who had progressed on initial treatment. High amounts of Programmed

Around 66 patients will be enrolled in this open label, non-randomized Phase I trial, which is divided into a dose-escalation phase and an expansion cohort phase. The trial